Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Elbit Medical Gains to 2-Week High on Unit’s U.S. Marketing

July 4 (Bloomberg) -- Elbit Medical Technologies Ltd. rose to the highest level in more than two weeks after the company with stakes in medical-device manufacturers said a unit expects to get permission in 2014 to market a product in the U.S.

Shares of the Tel Aviv-based company surged 5.5 percent to 0.134 shekel, the highest since June 19, at the 4:30 p.m. close in Tel Aviv.

Elbit Medical said Gamida Cell expects to get approval during 2014 to market its StemEx drug, for the treatment of leukemia and lymphoma, in the U.S. Elbit has a 30.8 percent stake in Gamida.

To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at

To contact the editor responsible for this story: Claudia Maedler at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.